SCHEMBL648195

SCHEMBL648195

CCCCn1c(CN(Cc2ccc3c(c2)OCO3)Cc2ccc3c(c2)OCO3)nnc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
TSHR P16473 4/20 0.49
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HSP90AA1 P07900 2/20 0.43
HSP90AB1 P08238 2/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649845 0.95 C5AR1 (0.60) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL648390 0.90 C5AR1 (0.54) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL1913049 0.83 C5AR1 (0.67) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL647999 0.83 C5AR1 (0.62) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL649661 0.82 C5AR1 (0.66) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL4767016 0.82 C5AR1 (0.75) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL651895 0.82 C5AR1 (0.65) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL1912761 0.82 C5AR1 (0.65) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL649605 0.82 C5AR1 (0.65) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL5134857 0.82 C5AR1 (0.60) C5AR1SMN1; SMN2TDP1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed